^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
467 A real-world retrospective study of immunotherapy in NSCLC patients with KRAS mutation
Published date:
11/04/2023
Excerpt:
Moreover, in the entire population, patients with TP53 mutation (11.0 months vs. 8.5 months, P=0.038), positive PD-L1 expression (9.0 months vs. 8.5 months, P=0.041), or common mutations such as KRAS G12C/G12D/G12V showed better PFS (PFS: 14.5 months vs. 8.0 months, P=0.045)....The patients were divided into two groups according to their timing of receiving immunotherapy, as 105 patients (63.3%) received first-line treatment (1L) and 61 (36.7%) received second-line and above treatment (2L+). The 1L group had better prognosis than the 2L+ group, reflected in ORR (50.5% vs. 29.5%, P=0.001), mPFS (13.5 months vs. 5.0 months, P < 0.001), and mOS (20.0 months vs. 11.0 months, P=0.004)....Bringing immunotherapy to first-line use in NSCLC patients with KRAS mutation might prolong their survival, and combination therapy is a preferable option compared to monotherapy.
DOI:
http://dx.doi.org/10.1136/jitc-2023-SITC2023.0467
Source:
Title:
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy
Published date:
03/11/2023
Excerpt:
CONTRADICTING EVIDENCE: The objective of this study was to retrospectively analyze all consecutive patients with advanced/metastatic, KRAS-positive NSCLC who were diagnosed at a single academic institution since the advent of immunotherapy....a numerically lower mOS was observed in patients harboring p.G12D and p.G12A (7.1 and 5.2 months, respectively).
DOI:
https://doi.org/10.1002/cncr.34731
Source:
Title:
Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
Published date:
07/11/2022
Excerpt:
PFS benefited to different degrees after first-line ICI-based treatment in each genetic classification. KRAS G12D even benefited from OS (p = 0.045)....The KRAS G12D subtype can benefit from OS in the ICIs/CHE group (p = 0.045)...the clinical outcome of KRAS-mutant NSCLC patients benefits from a first-line ICI-based therapeutic regime to varying degrees.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.3390/jcm11144003
Source:
Title:
KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer
Published date:
07/11/2022
Excerpt:
...we retrospectively collected the clinical information of patients with NSCLC harboring KRAS-G12D mutation after ICI monotherapy or chemo-immunotherapy (Supplementary Table S6)….Three (27.3%) patients were identified with partial response, 3 (27.3%) patients with stable disease....At the time of survival analysis, patients with NSCLC could obtain more benefit from chemo-immunotherapy with respect to PFS...patients with KRAS-G12D-mutant NSCLC receiving chemo-immunotherapy had better overall survival (OS) than those with ICI monotherapy (P = 0.002; Figure 8D).
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1002/cac2.12327
